No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)


Clinico-pharmacological group

Beta1- blocker

Mechanism of action

Selective beta1-adrenergic blocker without internal sympathomimetic activity and membrane stabilizing properties. Blocking in low doses of β1-adrenoreceptors of the heart, Bisoprolol reduces the catecholamine-stimulated formation of cAMP from ATP, reduces the intracellular current of Calcium ions. It has a negative chrono-, dromo-, batmo-and inotropic effect, inhibits conductivity and excitability, slows down AV conduction, reduces myocardial need for oxygen. Reduces heart rate at rest and under load. Reduces the activity of plasma renin. It has hypotensive, antiarrhythmic and antianginal effects.

With increasing doses, bisoprolol has beta.2-adrenoblokiruyuschee action.

At the beginning of the drug use (in the first 24 hours) as a result of the reciprocal increase in the activity of α-adrenoreceptors and the elimination of stimulation β2-Adrenoreceptors OPSS increases slightly. After 1-3 days OPSS returns to the initial level, and with long-term use it decreases.

The hypotensive effect of bisoprolol is due to a decrease in IOC, sympathetic stimulation of peripheral vessels, a decrease in the activity of the renin-angiotensin system (important for patients with initial renin hypersecretion), restoration of sensitivity in response to a decrease in blood pressure and effect on the central nervous system.In case of arterial hypertension, the effect occurs in 2-5 days, stable action - in 1-2 months.

The antianginal effect is due to a decrease in myocardial oxygen demand as a result of a decrease in heart rate and a decrease in contractility, a prolongation of diastole, and an improvement in myocardial perfusion. By increasing the end-diastolic pressure in the left ventricle and increasing the stretching of the muscle fibers of the ventricles can increase the need for oxygen, especially in patients with chronic heart failure.

The antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased cAMP, arterial hypertension), as well as a decrease in the rate of spontaneous excitation of sinus and ectopic pacemakers and slowing AV-conduct (mainly in the antegrade and, to a lesser extent, in retrograde directions through the AV node) and along additional paths.

In contrast to non-selective beta-blockers, when administered in moderate therapeutic doses, bisoprolol has a less pronounced effect on organs containing β2-adrenoreceptors (pancreas, skeletal muscles, smooth muscles of peripheral arteries, bronchi and uterus) and carbohydrate metabolism, does not cause sodium retention in the body. The severity of atherogenic action does not differ from that of propranolol.

When used in large doses, it has a blocking effect on both subtypes of β-adrenoreceptors.



After taking the drug inside of the gastrointestinal tract 80-90% of bisoprolol is absorbed.Reception simultaneously with food does not affect absorption. Cmax in blood plasma is achieved in 1-3 hours


Binding to plasma proteins is about 35%. Permeability through the BBB and placental barrier, as well as the degree of penetration into breast milk are low.

Metabolism and excretion

50% of the dose taken is metabolized in the liver to form inactive metabolites. 50% - displayed in unchanged form.

T1/2 makes up9-12 hours. About 98% of the substance excreted by the kidneys, less than 2% - with bile.

Indications for use of the drug

- arterial hypertension;

- IHD (prevention of strokes).

Dosage and administration

A single dose is 2.5-5 mg. Usually the initial dose is 5 mg 1 time / day. If necessary, increase the dose to 10 mg 1 time / day. The maximum daily intake for adults is 20 mg.

Tablets should be taken orally, in the morning, on an empty stomach, without chewing.

Treatment patients with impaired liver function or kidney mild or moderate usually does not require dose adjustment. Have patients with severe renal impairment (CC <20 ml / min) or the liver the maximum daily dose is 10 mg.

Have patients old age dose adjustment is not required.

Side effect

From the side of the central nervous system: fatigue, weakness, dizziness, headache, drowsiness or insomnia, nightmares, depression, anxiety, confusion or short-term memory loss, hallucinations, asthenia, myasthenia gravis, paresthesia in the extremities (in patients with intermittent claudication and Reino syndrome), tremor.

Special senses: blurred vision, decreased secretion of tear fluid, dry and sore eyes, conjunctivitis.

Cardiovascular: sinus bradycardia, palpitations, myocardial conduction disturbances, AV conduction disturbances (up to the development of complete transverse blockade and cardiac arrest), arrhythmias, weakening of myocardial contractility, development (aggravation) of chronic heart failure (swelling of ankles, feet; shortness of breath), reduction of blood pressure, orthostatic hypotension, manifestation of angiospasm (increased disturbance of peripheral circulation, cooling of the lower extremities, Raynaud's syndrome), chest pain.

Gastrointestinal: dry oral mucosa, nausea, vomiting, abdominal pain, constipation or diarrhea, abnormal liver function (dark urine, sclera or skin jaundice, cholestasis), changes in liver enzyme activity (increased ALT, ACT), bilirubin levels, triglycerides, changes taste.

Respiratory: nasal congestion, difficulty breathing when administered in high doses (due to loss of selectivity) and / or in susceptible patients - laryngo and bronchospasm.

On the part of the endocrine system: hyperglycemia (in patients with insulin-dependent diabetes mellitus), hypoglycemia (in patients receiving insulin), a hypothyroid state.

Dermatologic: increased sweating, skin hyperemia, rash, psoriasis-like skin reactions, exacerbation of psoriasis symptoms, alopecia.

Hemic and lymphatic: thrombocytopenia (unusual bleeding and hemorrhage), agranulocytosis, leukopenia.

Musculoskeletal system: muscle weakness, cramps in the calf muscles, back pain, arthralgia.

From the reproductive system: decreased libido and decreased potency.

Allergic reactions: skin itch, rash, urticaria.

Other: withdrawal syndrome (increased angina attacks, increased blood pressure).

Effect on the fetus: intrauterine growth retardation, hypoglycemia, bradycardia.

Contraindications to the use of the drug

- shock (including cardiogenic);

- collapse;

- pulmonary edema;

- acute heart failure;

- chronic heart failure in the stage of decompensation;

- AV block II and III degree (without pacemaker);

- sinoatrial block;


- severe bradycardia (heart rate <50 beats / min);

- Prinzmetal angina;

- Cardiomegaly (without signs of heart failure);

- arterial hypotension (systolic blood pressure <100 mmHg. Art., Especially in myocardial infarction);

- bronchial asthma and COPD in history;

- simultaneous administration of MAO inhibitors (with the exception of MAO type B);

- late stages of impaired peripheral circulation;

- Raynaud's disease;

- pheochromocytoma (without the simultaneous use of alpha-blockers);

- metabolic acidosis;

- children's and teenage age up to 18 years (efficiency and safety of use are not established);

- Hypersensitivity to other beta-blockers;

- hypersensitivity to the drug.

WITH caution the drug should be prescribed for liver failure, chronic renal failure, myasthenia, thyrotoxicosis, diabetes mellitus, stage I AV-blockade, depression (including history), psoriasis, old age.

Use of the drug during pregnancy and lactation

Use during pregnancy and lactation is possible if the potential benefit to the mother exceeds the risk of side effects in the fetus and child (such as intrauterine growth retardation, hypoglycemia, bradycardia).

Application for violations of the liver

Treatment of patients with mild or moderate hepatic impairment usually does not require dose adjustment. In patients with severe hepatic impairment, the maximum daily dose should not exceed 10 mg.

Application for violations of kidney function

Treatment of patients with mild to moderate renal impairment usually does not require dose adjustment. In patients with severe renal impairment (CC less than 20 ml / min.), The maximum daily dose should not exceed 10 mg.

special instructions

The patient should be aware that they should not abruptly interrupt the treatment or change the recommended dose without first consulting a doctor.

Monitoring patients receiving Cordinorm should include monitoring of heart rate and blood pressure (at the beginning of treatment - daily, then once every 3-4 months), ECG, determination of blood glucose in patients with diabetes mellitus (1 time in 4-5 months).In elderly patients, it is recommended to monitor renal function (1 time in 4-5 months).

The patient should be trained in the method of counting heart rate and instructed on the need for medical consultation with a heart rate of less than 50 bpm.

Before starting treatment in patients with a burdened broncho-pulmonary history, it is recommended to conduct a study of the function of external respiration.

In approximately 20% of patients with stenocardia, beta-blockers are ineffective. The main reasons for this are severe coronary atherosclerosis with a low ischemic threshold (HR less than 100 beats / min) and an increased end-diastolic volume of the left ventricle that violates the subendocardial blood flow.

When smoking, the effectiveness of beta-blockers below.

Patients using contact lenses should take into account that, during treatment, there may be a decrease in the production of tear fluid.

When using Cordinorm in patients with pheochromocytoma, there is a risk of development of paradoxical arterial hypertension (unless effective alpha adrenoblockade is previously achieved).

In patients with thyrotoxicosis, Cordinorm may mask certain clinical signs of thyrotoxicosis (for example, tachycardia). Abrupt withdrawal of the drug in patients with thyrotoxicosis is contraindicated, as it can strengthen the symptoms.

In diabetes mellitus, the effect of bisoprolol may mask the tachycardia caused by hypoglycemia. Unlike non-selective beta-adrenergic blockers, Cordinorm practically does not increase insulin-induced hypoglycemia and does not delay the recovery of glucose in the blood to normal levels.

With simultaneous treatment with clonidine, its reception can be stopped only a few days after the withdrawal of Cordinorm.

Perhaps the increased severity of hypersensitivity reactions and the lack of effect of the usual doses of epinephrine (adrenaline) on the background of burdened allergological history. If it is necessary to conduct a planned surgical treatment, the drug is discontinued 48 hours before the start of general anesthesia. If the patient took the drug before surgery, he should choose a drug for general anesthesia with a minimally negative inotropic effect.

Reciprocal activation of the vagus nerve can be eliminated by / in the introduction of atropine (1-2 mg).

Drugs that reduce the supply of catecholamines (for example, reserpine) can enhance the action of beta-blockers, so patients taking such combinations of drugs should be under constant medical supervision to detect arterial hypotension or bradycardia.

Cardioselective adrenergic blockers can be prescribed to patients with bronchospastic diseases in case of intolerance and / or ineffectiveness of other antihypertensive drugs, but the dose should be strictly controlled. Overdose is dangerous for the development of bronchospasm. In the case of elderly patients with increasing bradycardia (less than 50 beats / min), arterial hypotension (systolic blood pressure below 100 mm Hg), AV blockade, bronchospasm, ventricular arrhythmias, severe abnormal liver function and kidney, reduce the dose or stop treatment.

It is recommended to stop therapy in the development of depression caused by taking beta-blockers.

You can not abruptly interrupt treatment because of the danger of severe arrhythmias and myocardial infarction. Cancellation is carried out gradually, reducing the dose for 2 weeks or more (reduce the dose by 25% in 3-4 days).

The drug should be discontinued before the examination of the content in the blood and urine of catecholamines, normetanephrine, vanillyl almond acid, and titers of antinuclear antibodies.

Influence on ability to drive motor transport and control mechanisms

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.


Symptoms: arrhythmia, ventricular premature beats, severe bradycardia, AV-blockade, lowering blood pressure, chronic heart failure, cyanosis of the finger or palm nails, difficulty breathing, bronchospasm, dizziness, fainting, convulsions.

Treatment: gastric lavage and prescription absorbent drugs; symptomatic therapy: in case of the developed AV blockade - in / in the introduction of 1-2 mg of atropine, epinephrine (adrenaline) or staging a temporary pacemaker; for ventricular extrasystole - the introduction of Lidocaine (class IA drugs are not used); with a decrease in blood pressure - the patient should be in the Trendelenburg position; if there are no signs of pulmonary edema, then plasma-substituting solutions should be injected / in, with the ineffectiveness - administration of epinephrine (adrenaline), dopamine, dobutamine (to maintain chronotropic and inotropic action and eliminate pronounced decrease in blood pressure); in heart failure - the introduction of cardiac glycosides, diuretics, glucagon; with convulsions - in / in the introduction of diazepam; with bronchospasm - inhalation beta2-adrenostimulators.

Drug interaction

In patients receiving bisoprolol, allergens used for immunotherapy or allergen extracts for skin tests increase the risk of severe systemic allergic reactions or anaphylaxis.

Iodine radiopaque drugs for IV administration increase the risk of Anaphylactic reactions.

Phenytoin with the on / in the introduction and drugs for inhalation general anesthesia (derivatives of hydrocarbons) increase the severity of the cardiodepressive action and the likelihood of lowering blood pressure.

With the combined use of bisoprolol changes the effectiveness of insulin and oral hypoglycemic agents, masks the symptoms of developing hypoglycemia (tachycardia, increased blood pressure).

With simultaneous use of bisoprolol reduces the clearance of lidocaine and xanthines (except difillin) and increases their concentration in plasma, especially in patients with initially increased clearance of theophylline under the influence of smoking.

The antihypertensive effect of the drug when used together weakens NSAIDs (due to the delay of sodium ions and the blockade of prostaglandin synthesis by the kidneys), GCS and estrogens (due to the delay of sodium ions).

Cardiac glycosides, methyldopa, reserpine and guanfacine, slow calcium channel blockers (verapamil, diltiazem), Amiodarone and other antiarrhythmic drugs when used together with bisoprolol increase the risk of developing or worsening bradycardia, AV-blockade, cardiac arrest, and heart failure.

With simultaneous use of Nifedipine can lead to a significant reduction in blood pressure.

Diuretics, clonidine, sympatholytic, hydralazine, and other antihypertensive drugs, when applied simultaneously, can lead to an excessive decrease in blood pressure.

Cordinorm prolongs the action of non-depolarizing muscle relaxants and the anticoagulant effect of coumarins.

Tricyclic and tetracyclic antidepressants, antipsychotics (neuroleptics), ethanol, sedatives and hypnotic drugs increase the inhibitory effect of bisoprolol on the central nervous system.

It is not recommended simultaneous use with MAO inhibitors due to a significant increase in the hypotensive effect, the interval in treatment between taking MAO inhibitors and bisoprolol should be at least 14 days.

Unhydrogenated ergot alkaloids, when used together, increase the risk of developing disorders of the peripheral circulation.

Ergotamine when used together increases the risk of developing peripheral circulatory disorders.

Sulfasalazine increases plasma concentration of bisoprolol.

Rifampicin with simultaneous use shortens T1/2 bisoprolol.

Pharmacy sales terms

The drug is available on prescription.

Terms and conditions of storage

The drug should be stored out of the reach of children at a temperature not higher than 30 ° C.

42 Items